Myths vs facts: CYP2C19 and allergy

CYP2C19 is a drug-metabolizing enzyme primarily involved in processing medications like proton pump inhibitors (omeprazole), antidepressants, and clopidogrel. There is no direct scientific link between CYP2C19 variants and allergies. A common myth is that certain CYP2C19 genotypes cause or worsen allergies – this is false. The fact is: variants such as *2, *3, and *17 affect how fast or slow a person metabolizes certain drugs. In allergic patients, this could theoretically influence the efficacy of antihistamines or corticosteroids, but no robust clinical trials support adjusting allergy treatment based solely on CYP2C19 status. The evidence is mechanistic and pharmacokinetic, not allergy-specific. Direct-to-consumer tests that claim CYP2C19 predicts allergy risk are misleading. Caveat: CYP2C19 genotyping is clinically validated for drug dosing (e.g., clopidogrel), but not for allergy prevention or diagnosis.